Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Position Decreased by Signaturefd LLC

Signaturefd LLC decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 25.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,387 shares of the medical equipment provider’s stock after selling 471 shares during the period. Signaturefd LLC’s holdings in Zimmer Biomet were worth $147,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in ZBH. Stonebridge Financial Group LLC bought a new position in shares of Zimmer Biomet during the 4th quarter valued at about $25,000. Dunhill Financial LLC boosted its position in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Brooklyn Investment Group purchased a new stake in Zimmer Biomet during the third quarter valued at about $35,000. Kentucky Trust Co purchased a new stake in Zimmer Biomet during the fourth quarter valued at about $39,000. Finally, OFI Invest Asset Management purchased a new stake in Zimmer Biomet during the fourth quarter valued at about $40,000. Institutional investors own 88.89% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on ZBH. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Raymond James reduced their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Barclays reduced their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Finally, Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Trading Down 0.9 %

NYSE:ZBH opened at $110.79 on Friday. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The stock’s 50 day moving average price is $106.74 and its 200 day moving average price is $106.86. The company has a market capitalization of $22.05 billion, a P/E ratio of 24.90, a P/E/G ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the firm earned $2.20 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.95% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.